MIND THE GAP! How to Pave the Way to Access to Authorised ATMPs for Patients?
An event by the TRANSFORM MEP Interest Group
Advanced Therapies Medicinal Products (ATMPs) are highly personalised treatments with the potential to transform the lives of patients.
This meeting has brought together policy-makers (MEPs, representatives of EU institutions, national representatives), regulators (EMA), patient representatives, medical experts, scientists, researchers, industry representatives and academics to discuss recommended changes in policy and practice, and to offer solutions to unlock patients’ access to ATMPs in Europe.
MEP, Renew Europe Czechia
Dr. Alexander Natz
Jo De Cock
Administrateur Général Honoraire, INAMI-RIZIV
MEP, S&D, Czechia
Public Affairs Director, EURORDIS-Rare Disease Europe
Special Advisor HTA, Dutch National Health Care Institute (ZIN)
Head of Market Access EMEA, Novartis Gene Therapies
TRANSFORM Alliance Members
MEP, Renew Europe, Ireland
MEP, S&D, Italy